High-risk neuroblastoma

The PBS subsidises eflornithine for patients with high-risk neuroblastoma.

Patient eligibility

The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with eflornithine under the National Health Act 1953, section 100 for patients with high-risk neuroblastoma.

Patients must be eligible for the PBS and meet the relevant restriction criteria.

The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing eflornithine.

Section 100 arrangements

eflornithine

This item is only PBS-subsidised for non-admitted patients, day admitted patients, or patients on discharge who are attending either:

  • an approved private hospital
  • a public hospital.

This item isn’t PBS-subsidised for public hospital in-patients. You must include the hospital name and provider number on the authority application form.

Treatment specifics

To be eligible for PBS-subsidised treatment with eflornithine, patients must be treated by either a:

  • paediatric oncologist
  • haematologist.

Authority applications

Applying for initial treatment

Please note: You’ll get an immediate assessment when you request PBS authorities online.

Applications for initial authority approval to prescribe PBS-subsidised eflornithine to treat high-risk neuroblastoma can be made:

All written applications must include:

Applying for initial grandfather treatment

For patients who received non-PBS-subsidised eflornithine treatment before 1 August 2025 for high-risk neuroblastoma, apply for initial grandfather authority approval either:

Applying for continuing treatment

Applications for continuing authority approval to prescribe PBS-subsidised eflornithine to treat high-risk neuroblastoma can be made either:

More information

Call the PBS Complex Drugs Programs enquiry line for more information.

Page last updated: 1 August 2025.
QC 83023